Pharmacological action

Recombinant chorionic gonadotropin. It has the same amino acid sequence as chHG contained in the urine. Binds transmembrane receptors on the cell surface LH theca and granulosa of the ovary. It ootsitarnogo initiation of meiosis, ovulation (ovulation), the formation of the corpus luteum. Stimulates the production of progesterone and estradiol luteum.


After sc administration the absolute bioavailability of about 40%, T 1 / 2 - 30 hours


Used in combination of assisted reproductive technologies (including those for in vitro fertilization) to the induction of final maturation of follicles and lyuteinizatsii after stimulation of gonadotropin therapy.

When anovulyatornom or oligoovulyatornom infertility for induction of ovulation and lyuteinizatsii at the end of stimulation of growth of the follicles.

Dosage regimen

Enter n / k. Single dose - 250 micrograms. Multiplicity introduction depends on indications and treatment regimens.

Side effect

From the side of the central nervous system: possible headache, fatigue, seldom - depression, irritability, anxiety.

On the part of the digestive system: nausea, vomiting, abdominal pain, rarely - diarrhea.

On the part of the reproductive system: possible ovarian hyperstimulation syndrome, rarely - ovarian hyperstimulation syndrome of severe, painful mammary glands.


Tumors in the hypothalamus and pituitary, ovary bulk tumor or cyst, not associated with polycystic ovarian, vaginal bleeding of unknown origin, ovarian, uterine, breast, ectopic pregnancies during the 3 previous months; thromboembolism, primary ovarian insufficiency, congenital malformations of sexual organs incompatible with pregnancy, uterine fibroids, is incompatible with pregnancy; Postmenopause; sensitivity to horiogonadotropinu alpha.


Before treatment is necessary to establish the causes of infertility in the patient and her partner, and to assess the expected risk factors for the occurrence of pregnancy. Especially should be considered symptoms of hypothyroidism, adrenal insufficiency, hyperprolactinemia, the presence of tumors in the hypothalamic-pituitary region, used specific methods of therapy.

To reduce the risk of ovarian hyperstimulation syndrome should closely monitor the response of the ovaries with ultrasound and determination of estradiol in the blood before treatment and during it.

Compared with natural fertilization during stimulation increases the risk of multiple pregnancies. In most cases, twins are born. In applying the techniques of assisted reproduction number of live births corresponds to the number of embryos transferred into the uterus.

Introduction horiogonadotropina alpha may affect the immunological picture chHG levels in serum and urine for 10 days and cause a false positive reaction for pregnancy tests.

Against the background of horiogonadotropina alpha, mild stimulation of thyroid function.